KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Idexx Laboratories (IDXX) EBT (2016 - 2026)

Idexx Laboratories has reported EBT over the past 17 years, most recently at $307.0 million for Q4 2025.

  • For Q4 2025, EBT rose 19.73% year-over-year to $307.0 million; the TTM value through Dec 2025 reached $1.3 billion, up 19.31%, while the annual FY2025 figure was $1.3 billion, 19.31% up from the prior year.
  • EBT for Q4 2025 was $307.0 million at Idexx Laboratories, down from $344.8 million in the prior quarter.
  • Over five years, EBT peaked at $362.4 million in Q2 2025 and troughed at $171.1 million in Q2 2022.
  • A 5-year average of $262.9 million and a median of $257.7 million in 2024 define the central range for EBT.
  • Biggest five-year swings in EBT: skyrocketed 75.54% in 2021 and later crashed 32.04% in 2022.
  • Year by year, EBT stood at $191.9 million in 2021, then increased by 11.12% to $213.2 million in 2022, then increased by 12.41% to $239.7 million in 2023, then grew by 6.98% to $256.4 million in 2024, then grew by 19.73% to $307.0 million in 2025.
  • Business Quant data shows EBT for IDXX at $307.0 million in Q4 2025, $344.8 million in Q3 2025, and $362.4 million in Q2 2025.